Propanc Health Group Corp (OTCMKTS:PPCH) Climbing Up The Charts

Shares of Propanc Health Group Corp (OTCMKTS:PPCH) have been surging up the charts ever since our last article. We alerted our subscribers that the stock was indeed making a comeback and that shares were bound to bounce higher as long as they could overcome selling from toxic financiers. This is quite a turnaround for a company that was on a downtrend for all of last year and the better part of this year on the back of toxic financings that have diluted shareholders.Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancers. PPCH has developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Its products involve or employ proenzymes, which are inactive precursors of enzymes. The company says that "in the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening."The latest data confirmed a synergistic response to a broad range of cancer indications, which also includes kidney, melanoma, brain, prostate, liver, uterine and lung cancers. The data provided compelling evidence that PRP has the potential to fight a broad range of cancer types, some with high unmet medical needs, which the company will look towards investigating through clinical trials. Furthermore, data from the recent cell line studies tested at the R&D facility of its contract research partner, vivoPharm LLC, in Hershey, PA, showed a synergistic response between the two active components, trypsinogen and chymotrypsinogen, further strengthening its lead patent claims in key jurisdictions such as North America and Europe.Last week, PPCH announced that it had filed two more patent applications in the United States regarding new compositions of its lead product, PRP, for treating cancer. The inventions summarize different combinations of the two proenzymes, trypsinogen and chymotrypsinogen, which synergistically enhance their anti-cancer effects, compared to when used in a one to one ratio, or as singular agents. The combinations are in addition to the preferred combination for PRP, and supplements the company's patent position across a broad range of cancers.PPCH also said that it plans to meet soon with MHRA (Medicines and Healthcare Products Regulatory Agency) to discuss formal preclinical and clinical development activities for PRP. Management also intends to apply for orphan drug designation for pancreatic and ovarian cancers in the US and EU in the near future as well, should they satisfy the necessary criteria.Last month, Propanc announced that received $1.2 million from an institutional investor in order to fast track its preclinical activities, including GMP (Good Manufacturing Practice) manufacturing and preparation for future patient trials, which the Company hopes to file an application for this year. Propanc said that "the additional funds provides an opportunity for the company to fast track the development of PRP into patient trials. Key activities anticipated include completion of a 28 day animal safety toxicology study, development of bioanalytical methods for animals and humans in order to assess the movement of the drug within the body, and preparation of GMP manufacture of PRP for patient trials."The company is also presently compiling results from its recent 14 day dose range finding study in rats, which will be used to determine appropriate dosing levels for the upcoming 28 day toxicology study. The data will be incorporated into the submission for the MHRA in order to discuss the next stage of development activities, which could lead into early stage patient trials in 2016, or first quarter 2017.Currently trading with a market cap of just under $20 million, PPCH is an exciting story on the OTC markets with some intriguing science behind the company. If the company can deliver, shares will be off to the races and we'll see PPCH turn into a microcap runner. We will be updating Insider Financial as soon as we know more. For continuing coverage on PPCH, sign up for our free newsletter today and get our next hot stock pick!Disclosure: We have no position in PPCH and have not been compensated for this article.